2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors

Thorsten Simon*, Barbara Hero, Johannes H. Schulte, Hedwig Deubzer, Patrick Hundsdoerfer, Dietrich Von Schweinitz, Jörg Fuchs, Matthias Schmidt, Vikas Prasad, Barbara Krug, Beate Timmermann, Ivo Leuschner, Matthias Fischer, Thorsten Langer, Kathy Astrahantseff, Frank Berthold, Holger Lode, Angelika Eggert

*Korrespondierende/r Autor/-in für diese Arbeit
18 Zitate (Scopus)

Abstract

The clinical course of neuroblastoma is more heterogeneous than any other malignant disease. Most low-risk patients experience regression after limited or even no chemotherapy. However, more than half of high-risk patients die from disease despite intensive multimodal treatment. Precise patient characterization at diagnosis is key for risk-adapted treatment. The guidelines presented here incorporate results from national and international clinical trials to produce recommendations for diagnosing and treating neuroblastoma patients in German hospitals outside of clinical trials.

OriginalspracheEnglisch
ZeitschriftKlinische Padiatrie
Jahrgang229
Ausgabenummer3
Seiten (von - bis)147-167
Seitenumfang21
ISSN0300-8630
DOIs
PublikationsstatusVeröffentlicht - 01.05.2017

Fingerprint

Untersuchen Sie die Forschungsthemen von „2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren